SIL 1002
Alternative Names: SIL-1002; SL-1002Latest Information Update: 26 Sep 2023
At a glance
- Originator Saol Therapeutics
- Class Analgesics; Antispastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Muscle spasticity; Musculoskeletal pain
Most Recent Events
- 19 Sep 2023 Saol Therapeutics plans a phase III trial for Limb Spasticity and Knee pain associated with Osteoarthritis
- 19 Sep 2023 Saol Therapeutics completes enrolment in the phase II COMPASS trial for Musculoskeletal pain in the US (NCT05470608)
- 19 Sep 2023 Saol Therapeutics completes enrolment in the phase II RAISE Spasticity trial for Muscle Spasticity in the US (NCT05311215)